http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2538697-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cf55d0a88f05b95fbd01f520b5ba93f2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-198 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-21 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P39-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04 |
| filingDate | 2013-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb025c9fca18402981d0d719035b5f9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e464992c49ed1955711535b2dad074c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f96741c7a6123175b698fa025c580637 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8e2a06c17685f2d63eeecb4ab745d4d1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_92dfc04ee408c9d9adf38b9fd51340ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c484e0890b78b9d19d62321fe022cd5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f697eab879bac76656e57bf658b3314 |
| publicationDate | 2015-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2538697-C1 |
| titleOfInvention | Pharmaceutical composition for treating gastroduodenal ulcer, possessing immunomodulatory, antiviral, antibacterial, anti-inflammatory, antioxidant and regenerative effect in form of tablets, capsules or gel |
| abstract | FIELD: medicine, pharmaceutics. n SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E. n EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect. n 6 cl, 5 ex |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2020071953-A1 |
| priorityDate | 2013-06-11-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 152.